Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations ... Genesis of Lung Adenocarcinoma Feb ...

A laboratory study provides evidence about how advanced age can be protective against cancer -- with implications for treating patients in different age groups.

It's long been thought that age is the most significant risk factor for cancer since, over time, genetic mutations accumulate ...

The TGF-beta and RAS signaling pathways work together to spur the spread of cancer in lung adenocarcinoma, a leading cause of ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

Sabari, MD, which focused on the first-line approval of amivantamab (Ami; Rybrevant; Johnson & Johnson) plus lazertinib ...

Aging induces iron deficiency, reducing stem cell function and tumor growth while enhancing ferroptosis resistance, revealing ...

Bizengri (zenocutuzumab) targets the NRG1 gene and has been cleared by the FDA to treat advanced pancreatic adenocarcinoma ...

The FDA approved Bizengri (zenocutuzumab-zbco) for advanced unresectable or metastatic NRG1+ NSCLC or pancreatic adenocarcinoma.

That’s because genetic mutations build up in cells over years and ... the MSK research team studied a genetically modified ...